Literature DB >> 6360325

Efficacy of prolonged intermittent therapy with combined 5-fluorouracil and methyl-CCNU following resection for carcinoma of the large bowel. A Veterans Administration Surgical Oncology Group report.

G A Higgins, J H Amadeo, J McElhinney, J J McCaughan, R J Keehn.   

Abstract

This prospective evaluation of 5-FU and methyl-CCNU administered in combination to patients with curative surgery for histologically proved colorectal adenocarcinoma is based upon 645 patients randomized between August 1973 and July 1979. Beyond the requirement that the resection be clinically and microscopically complete, patients were not stratified prior to random treatment assignment to surgery alone or surgery followed by adjuvant chemotherapy. Drug therapy consisted of discrete 5-day courses administered at 7-week intervals, start to start. Toxic reactions were reported in association with 40% of courses. In 10% of patients with hematologic toxicity, the reactions were sufficiently severe to require the suspension or discontinuation of treatment. Treated patients experienced a slightly more favorable survival than did controls. However, the advantage was seen only in the 216 patients (34% of total) with one to four positive lymph nodes in the resected specimen. Similar proportions of treated and control deaths were attributed to residual or recurrent disease.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6360325     DOI: 10.1002/1097-0142(19840101)53:1<1::aid-cncr2820530102>3.0.co;2-l

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  20 in total

1.  Chemosensitivity tests in colorectal cancer patients.

Authors:  E Yanagawa; M Nishiyama; T Saeki; R Kim; K Jinushi; Y Kirihara; S Takagami; M Niimoto; T Hattori
Journal:  Jpn J Surg       Date:  1989-07

Review 2.  Surgical excision alone is adequate treatment for primary colorectal cancer.

Authors:  R Hind; D R Rew; C D Johnson
Journal:  Ann R Coll Surg Engl       Date:  1992-01       Impact factor: 1.891

3.  Observer variability in histopathological reporting of transitional cell carcinoma and epithelial dysplasia in bladders.

Authors:  A J Robertson; J S Beck; R A Burnett; S R Howatson; F D Lee; A M Lessells; K M McLaren; S M Moss; J G Simpson; G D Smith
Journal:  J Clin Pathol       Date:  1990-01       Impact factor: 3.411

4.  Adjuvant treatment in colorectal cancer: an update.

Authors:  H O Douglass
Journal:  World J Surg       Date:  1987-08       Impact factor: 3.352

5.  The prognostic value of the modifications of the Dukes' C class of colorectal cancer. An analysis of the NSABP clinical trials.

Authors:  N Wolmark; B Fisher; H S Wieand
Journal:  Ann Surg       Date:  1986-02       Impact factor: 12.969

6.  Intraportal chemotherapy in colorectal carcinoma as an adjuvant modality.

Authors:  U Metzger; B Mermillod; P Aeberhard; F Gloor; A Bissat; R Egeli; U Laffer; S Martinoli; W Mueller; R Schroeder
Journal:  World J Surg       Date:  1987-08       Impact factor: 3.352

7.  Retrospective study of prognostic importance of DNA flow cytometry of urinary bladder carcinoma.

Authors:  C E Blomjous; N W Schipper; J P Baak; E M van Galen; H J de Voogt; C J Meyer
Journal:  J Clin Pathol       Date:  1988-01       Impact factor: 3.411

Review 8.  Colorectal cancer.

Authors:  L D Leffall
Journal:  J Natl Med Assoc       Date:  1985-04       Impact factor: 1.798

Review 9.  Chemotherapy and immunotherapy of colorectal cancer.

Authors:  G Masucci; P Ragnhammar; J E Frödin; A L Hjelm; P Wersäll; J Fagerberg; A Osterborg; H Mellstedt
Journal:  Med Oncol Tumor Pharmacother       Date:  1991

10.  Clinical and immunological evaluation of 20 patients with advanced colorectal cancer treated with high dose recombinant leukocyte interferon-alpha A (rIFN alpha A).

Authors:  A M Eggermont; W Weimar; B Tank; A M Dekkers-Bijma; R L Marquet; J S Lameris; D L Westbroek; J Jeekel
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.